Christopher Rovaldi

Insider Reports History

Entity
Individual
Location
C/O Acceleron Pharma Inc., 128 Sidney St., Cambridge, MA
Signature
/s/ Keith Regnante, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Rovaldi:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Keros Therapeutics, Inc. Chief Operating Officer Common Stock 60K $2.64M $44.01 Feb 18, 2025 Direct

Insider Reports Filed by Christopher Rovaldi

Symbol Company Period Transactions Value $ Form Type Date Filed Role
KROS Keros Therapeutics, Inc. Feb 18, 2025 1 $0 4 Feb 19, 2025 Chief Operating Officer
KROS Keros Therapeutics, Inc. Feb 13, 2024 1 $0 4 Feb 15, 2024 CHIEF OPERATING OFFICER
KROS Keros Therapeutics, Inc. Feb 16, 2023 1 $0 4 Feb 17, 2023 Chief Operating Officer
KROS Keros Therapeutics, Inc. Apr 6, 2022 3 -$84.7K 4 Apr 8, 2022 Chief Operating Officer
KROS Keros Therapeutics, Inc. Apr 1, 2022 7 -$35.9K 4 Apr 5, 2022 Chief Operating Officer
KROS Keros Therapeutics, Inc. Feb 1, 2022 1 $0 4 Feb 3, 2022 Chief Operating Officer
KROS Keros Therapeutics, Inc. Feb 1, 2022 0 $0 3 Feb 3, 2022 Chief Operating Officer